Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Prospective Grant of Exclusive License: Commercializing Instruments, Reagents and Related Products Used for Sequencing of Single Nucleic Acid Molecules on a Substrate, Based on High Speed Parallel Molecular Nucleic Acid Sequencing Method Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before October 4, 2004 will be considered.
View Prospective Grant of Exclusive License: Methods and Compositions for the Promotion of Hair Growth Utilizing Actin Binding Peptides Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before October 1, 2004 will be considered.
View Prospective Grant of Exclusive License: Activation of Recombinant Diphtheria Toxin Fusion Proteins by Specific Proteases Highly Expressed on the Surface of Tumor Cells Only written comments and/or license applications which are received by the National Institutes of Health on or before September 14, 2004 will be considered.
View Prospective Grant of Exclusive License: Human-Bovine Reassortant Rotavirus Vaccine Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before September 20, 2004 will be considered.
View Prospective Grant of Exclusive License: Human-Bovine Reassortant Rotavirus Vaccine Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before September 7, 2004 will be considered.
View Prospective Grant of Exclusive License: 1,8-Naphthalimide Imidazo [4,5,1-de] Acridones With Anti-Tumor Activity Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 16, 2004 will be considered.
View Prospective Grant of an Exclusive License: Interleukin-2 Stimulated T Lymphocyte Cell Death for the Treatment of Autoimmune Diseases, Allergic Responses, and Graft Rejection Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before June 28, 2004 will be considered.
View Prospective Grant of Exclusive License: Human Monoclonal Antibody Therapeutics for the Treatment of Hepatitis C (HCV) Infections Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before June 14, 2004, will be considered.
View Prospective Grant of Exclusive License: Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in The 3′-UTR of Dengue Types 1,2,3, And 4 Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before June 7, 2004, will be considered.
View Prospective Grant of Exclusive License: Use of Inhibitors of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase as a Modality in Cancer Therapy Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before June 1, 2004, will be considered.
View Prospective Grant of Exclusive License: Methods and Compositions for the Promotion of Hair Growth Utilizing Actin Binding Peptides Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 24, 2004, will be considered.
View Prospective Grant of Exclusive License: Immunoconjugate for the Treatment of Mesothelin-Expressing Cancers Only written comments and/or license applications which are received by the National Institutes of Health on or before May 10, 2004, will be considered.
View Prospective Grant of Exclusive License: Zap 70 Protein Expression in Chronic Lymphocytic Leukemia (CLL) Only written comments and/or license applications which are received by the National Institutes of Health on or before May 3, 2004 will be considered.
View National Heart, Lung, and Blood Institute (NHLBI); Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Development of a Novel Endotracheal Tube Cleaning System and Improved Endotracheal Tube Design and Conditions of Use
View Prospective Grant of Exclusive License: Combined Growth Factor-Deleted and Thymidine Kinase-Deleted Vaccinia Virus Vector Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before April 20, 2004, will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: The Use of Geldanamycin and Its Derivatives for the Treatment of Cancer Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before April 13, 2004 will be considered.
View Prospective Grant of Exclusive License: Probe Using Diffuse-Reflectance Spectroscopy Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before April 13, 2004 will be considered.
View Prospective Grant of Exclusive License: Construction of West Nile Virus and Dengue Virus Chimeras for Use in a Live Virus Vaccine To Prevent Disease Caused by West Nile Virus Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before April 13, 2004 will be considered.
View Prospective Grant of Exclusive License: Diagnostics of Fungal Infections N/A.
View Prospective Grant of Exclusive License: Method of Treating Cancer in Humans Using IL-21 Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before March 16, 2004, will be considered.
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Use of Mutants of Human Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3) in Treatment of Cancer Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before February 20, 2004 will be considered.
View Government-Owned Inventions; Availability for Licensing